Key statistics
On Friday, Halozyme Therapeutics Inc (RV7:MUN) closed at 52.98, -9.96% below its 52-week high of 58.84, set on Aug 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 53.14 |
---|---|
High | 53.14 |
Low | 52.98 |
Bid | 52.98 |
Offer | 53.18 |
Previous close | 53.80 |
Average volume | 76.70 |
---|---|
Shares outstanding | 126.68m |
Free float | 125.31m |
P/E (TTM) | 22.97 |
Market cap | 7.50bn USD |
EPS (TTM) | 2.58 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 16:25 BST.
More ▼
Press releases
- Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
- Halozyme to Present at Upcoming Investor Conferences
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Halozyme to Report Second Quarter 2024 Financial and Operating Results
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
More ▼